Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Moved Up to "Sell" by Wall Street Zen

Key Points

• Wall Street Zen upgraded Verrica Pharmaceuticals from “strong sell” to “sell,” while analysts overall have a consensus “Hold” rating and an average price target of $12.67.
• VRCA opened at $4.37, with a market capitalization of approximately $75.1 million and a share price range of $3.28 to $9.82 over the past year.
• Renaissance Technologies increased its stake by 22.6%, and institutional investors collectively own 42.45% of Verrica Pharmaceuticals. The company’s lead product, YCANTHE, is FDA-approved to treat molluscum contagiosum.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued research reports about the company. Lake Street Capital began coverage on Verrica Pharmaceuticals in a research note on Thursday, August 27th. They issued a "buy" rating and a $9.00 target price for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $12.67.

Verrica Pharmaceuticals Stock Performance

Verrica Pharmaceuticals stock opened at $4.37 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.45 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $75.08 million, a PE ratio of -2.62 and a beta of 1.49. The firm has a fifty day simple moving average of $5.06 and a two-hundred day simple moving average of $5.70. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82.

Institutional Trading of Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 22.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,360 shares of the company's stock after purchasing an additional 5,960 shares during the period. Renaissance Technologies LLC owned about 0.19% of Verrica Pharmaceuticals worth $171,000 at the end of the most recent reporting period. Institutional investors own 42.45% of the company's stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company's work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options.

Verrica's lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.